New PET tracer aims to spot hidden scarring in Crohn's patients

NCT ID NCT07273188

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether a special PET scan tracer, Ga68-FAPI-46, can detect early fibrosis (scarring) in the small bowel of people with Crohn's disease. About 45 participants will be divided into those with known strictures and those without, to compare scan results. The goal is to improve diagnosis of fibrostenosing Crohn's, which currently is hard to detect early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ga68-FAPI-46 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a new way to detect early scarring in Crohn's disease, helping doctors identify and treat fibrosis before it causes blockages.
What could go wrong
This is a very early, small study (45 people) testing a diagnostic method, not a treatment. The tracer may not reliably distinguish early fibrosis from inflammation, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.